Helix BioPharma Corp. (TO:HBP) — Market Cap & Net Worth
Market Cap & Net Worth: Helix BioPharma Corp. (HBP)
Helix BioPharma Corp. (TO:HBP) has a market capitalization of $80.11 Million (CA$110.75 Million) as of September 19, 2026. Listed on the TO stock exchange, this Canada-based company holds position #20165 globally and #688 in its home market, demonstrating a -4.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Helix BioPharma Corp.'s stock price CA$1.45 by its total outstanding shares 76378098 (76.38 Million). Also see Helix BioPharma Corp. asset portfolio for a full breakdown of the balance sheet.
Helix BioPharma Corp. Market Cap History: 2015 to 2026
Helix BioPharma Corp.'s market capitalization history from 2015 to 2026. Data shows change from $552.51 Million to $80.11 Million (-16.58% CAGR). Also see HBP cash generation efficiency for how efficiently the company converts equity into cash flow.
Helix BioPharma Corp. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Helix BioPharma Corp.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Helix BioPharma Corp. for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HBP by Market Capitalization
Companies near Helix BioPharma Corp. in the global market cap rankings as of September 19, 2026. Review tangible equity quality of Helix BioPharma Corp. to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Helix BioPharma Corp. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Helix BioPharma Corp. Historical Marketcap From 2015 to 2026
Between 2015 and today, Helix BioPharma Corp.'s market cap moved from $552.51 Million to $ 80.11 Million, with a yearly change of -16.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$80.11 Million | -38.82% |
| 2025 | CA$130.94 Million | +166.29% |
| 2024 | CA$49.17 Million | -15.24% |
| 2023 | CA$58.01 Million | -4.55% |
| 2022 | CA$60.78 Million | -26.67% |
| 2021 | CA$82.88 Million | -40.00% |
| 2020 | CA$138.13 Million | -62.69% |
| 2019 | CA$370.18 Million | +152.83% |
| 2018 | CA$146.41 Million | -43.62% |
| 2017 | CA$259.68 Million | -38.96% |
| 2016 | CA$425.43 Million | -23.00% |
| 2015 | CA$552.51 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Helix BioPharma Corp. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $80.11 Million USD |
| MoneyControl | $80.11 Million USD |
| MarketWatch | $80.11 Million USD |
| marketcap.company | $80.11 Million USD |
| Reuters | $80.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical tria… Read more